Lysosomal Dysfunction in Progressive Supranuclear Palsy

Migration, Crosslink

📖

Lysosomal Dysfunction in Progressive Supranuclear Palsy

active

wiki page Created: 2026-04-02T07:19:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-lysosomal-dysfunction-ps

📖 Wiki Page

mechanism3018 wordssynced 2026-04-02

Lysosomal Dysfunction in Progressive Supranuclear Palsy

Overview

Progressive supranuclear palsy (PSP) is a rare neurodegenerative disorder characterized by progressive postural instability, vertical gaze palsy, akinesia, and cognitive impairment. While traditionally classified as a tauopathy alongside Alzheimer's disease, emerging evidence indicates that lysosomal dysfunction plays a critical role in PSP pathogenesis. The accumulation of autophagic vacuoles, impaired protein degradation, and lysosomal membrane permeabilization contribute to the characteristic tau pathology and neuronal loss observed in PSP[@autophagic2000][@lysosomal2008].

PSP represents one of the most common atypical parkinsonian disorders, with an estimated prevalence of 5-7 per 100,000 individuals worldwide. The disease typically presents in the sixth to seventh decade of life, with a mean disease duration of 6-9 years. The neuropathological hallmark of PSP is the accumulation of hyperphosphorylated tau protein in the form of neurofibrillary tangles, globose tangles, and tufted astrocytes, particularly in the basal ganglia, brainstem, and cerebellar structures. However, mounting evidence suggests that lysosomal dysfunction is not merely a downstream consequence of tau pathology but rather a primary driver of neurodegeneration in PSP[@autophagic2000][@lysosomal2000].

Lysosomal Biology in the Brain

The Lysosomal System

...

Lysosomal Dysfunction in Progressive Supranuclear Palsy

Overview

Progressive supranuclear palsy (PSP) is a rare neurodegenerative disorder characterized by progressive postural instability, vertical gaze palsy, akinesia, and cognitive impairment. While traditionally classified as a tauopathy alongside Alzheimer's disease, emerging evidence indicates that lysosomal dysfunction plays a critical role in PSP pathogenesis. The accumulation of autophagic vacuoles, impaired protein degradation, and lysosomal membrane permeabilization contribute to the characteristic tau pathology and neuronal loss observed in PSP[@autophagic2000][@lysosomal2008].

PSP represents one of the most common atypical parkinsonian disorders, with an estimated prevalence of 5-7 per 100,000 individuals worldwide. The disease typically presents in the sixth to seventh decade of life, with a mean disease duration of 6-9 years. The neuropathological hallmark of PSP is the accumulation of hyperphosphorylated tau protein in the form of neurofibrillary tangles, globose tangles, and tufted astrocytes, particularly in the basal ganglia, brainstem, and cerebellar structures. However, mounting evidence suggests that lysosomal dysfunction is not merely a downstream consequence of tau pathology but rather a primary driver of neurodegeneration in PSP[@autophagic2000][@lysosomal2000].

Lysosomal Biology in the Brain

The Lysosomal System

Lysosomes are membrane-bound organelles containing hydrolytic enzymes that degrade proteins, lipids, nucleic acids, and carbohydrates. In neurons, lysosomes function as critical regulators of protein homeostasis through multiple degradation pathways:

Macroautophagy: Bulk degradation of cytoplasmic components via autophagosomes that fuse with lysosomes
Microautophagy: Direct engulfment of cytoplasmic material by lysosomal membrane invagination
Chaperone-mediated autophagy (CMA): Selective import of proteins containing KFERQ motifs through LAMP-2A
Endocytosis: Degradation of extracellular materials internalized via clathrin-mediated endocytosis

The lysosomal membrane contains over 50 hydrolytic enzymes, including cathepsins B, D, L, and H, which require an acidic internal pH (pH 4.5-5.0) for optimal activity. This acidification is maintained by the vacuolar-type H+-ATPase (V-ATPase), which pumps protons into the lysosomal lumen[@gba2015].

Neuronal Lysosomal Function

Neurons rely heavily on lysosomal function due to their post-mitotic nature and high metabolic activity. The autophagy-lysosome pathway is essential for:

Degradation of misfolded proteins and protein aggregates
Turnover of organelles (mitophagy)
Synaptic vesicle recycling
Axonal transport of degradative materials
Regulation of synaptic plasticity through protein turnover

Neuronal lysosomes are actively transported along axons via microtubule-based motor proteins, allowing for distal degradation of materials in synaptic terminals. This axonal transport is particularly important in long projecting neurons such as dopaminergic neurons of the substantia nigra, which are selectively vulnerable in PSP[@mapt2007].

Lysosomal Subpopulations in Neurons

Recent research has revealed heterogeneity in neuronal lysosomes:

Somatic lysosomes: Large, perinuclear lysosomes involved in general protein homeostasis
Synaptic lysosomes: Smaller vesicles at presynaptic terminals specialized for synaptic vesicle recycling
Axonal lysosomes: Mobile vesicles transporting degradative materials toward the cell body

This specialization is critical for understanding PSP pathophysiology, as the affected brain regions in PSP contain neurons with particularly long axons and high synaptic activity.

Lysosomal Dysfunction in PSP

Evidence from Post-Mortem Studies

Post-mortem brain studies in PSP patients reveal consistent lysosomal abnormalities:

Accumulation of autophagic vacuoles: Electron microscopy shows widespread autophagic vacuoles in neurons and glia[@autophagic2000]
Lysosomal membrane permeabilization: Loss of lysosomal integrity releases cathepsins into the cytoplasm[@lysosomal2008]
Reduced lysosomal enzyme activity: Decreased activity of cathepsins B, D, and L in affected brain regions[@lysosomal2000]
Impaired autophagic flux: Accumulation of LC3-II and p62 indicates blockade of autophagy
Lipofuscin accumulation: Age-related lipofuscin deposits are significantly increased in PSP brains

The pattern of lysosomal dysfunction in PSP differs from other neurodegenerative diseases. While Alzheimer's disease shows prominent lysosomal distension and cathepsin activation, and Parkinson's disease exhibits specific impairments in mitophagy, PSP demonstrates a generalized disruption of the autophagic flux with particular emphasis on macroautophagy impairment[@autophagic2000][@tau2015].

Genetic Associations

While PSP is not typically considered a genetic lysosomal storage disorder, genetic variants affecting lysosomal function modify risk:

GBA mutations: Heterozygous glucocerebrosidase (GBA) mutations increase PSP risk, suggesting lysosomal glucocerebrosidase activity influences tauopathy[@gba2015]
MAPT H1 haplotype: The H1 tau haplotype is the major genetic risk factor and may affect lysosomal function[@mapt2007]
TPPP/p25α: This tubulin polymerization-promoting protein accumulates in PSP brain and affects lysosomal function
DNAJC13: Mutations in this DNAJ co-chaperone affect autophagy and lysosomal trafficking

The identification of GBA mutations as a risk factor for PSP is particularly significant, as it establishes a direct link between lysosomal glucocerebrosidase activity and tauopathy pathogenesis. GBA encodes glucocerebrosidase, a lysosomal enzyme that hydrolyzes glucosylceramide to glucose and ceramide. Heterozygous GBA mutations, which cause Gaucher disease in the homozygous state, are now recognized as the most significant genetic risk factor for Parkinson's disease and are also associated with increased risk for PSP and dementia with Lewy bodies[@gba2015][@lysosomal2017].

Lysosomal Protein Alterations in PSP

Proteomic studies of PSP brain tissue have identified specific lysosomal protein alterations:

| Protein | Change | Implication |
|---------|--------|-------------|
| Cathepsin B | Decreased activity | Impaired protein degradation |
| Cathepsin D | Decreased activity | Tau cleavage dysfunction |
| Cathepsin L | Decreased activity | Reduced autophagic flux |
| LAMP-2 | Reduced expression | Impaired CMA |
| LAMP-1 | Reduced expression | Lysosomal membrane instability |
| V-ATPase | Impaired function | Defective acidification |

Molecular Mechanisms

Tau and Lysosomal Interactions

The relationship between tau pathology and lysosomal dysfunction is bidirectional:

Tau accumulation impairs lysosomes: Pathological tau aggregates within lysosomes, disrupting their function[@tau2015]
Lysosomal failure promotes tau aggregation: Impaired protein clearance leads to increased tau oligomerization[@lysosomal2017]
Cathepsin-mediated tau cleavage: Certain cathepsins generate tau fragments that are more aggregation-prone
Tau-mediated lysosomal membrane damage: Direct interaction of tau with lysosomal membranes

Pathological tau can directly impair lysosomal function through multiple mechanisms. Tau oligomers can bind to lysosomal membranes, disrupting their integrity and promoting the release of hydrolytic enzymes into the cytoplasm. Additionally, tau accumulation within lysosomes can saturate the degradation capacity of these organelles, leading to the accumulation of autophagic vacuoles[@tau2015][@autophagy2015].

Autophagy-Lysosome Pathway Dysregulation

Multiple components of the autophagy-lysosome pathway are affected in PSP:

mTOR hyperactivation: Enhanced mTOR signaling inhibits autophagy initiation
LC3 lipidation defects: Impaired conversion of LC3-I to LC3-II
Syntaxin-17 dysfunction: This SNARE protein is required for autophagosome-lysosome fusion
V-ATPase impairment: Lysosomal acidification defects reduce hydrolytic activity
Atg5/Atg7 dysregulation: Key autophagy proteins show altered expression

The mTOR (mammalian target of rapamycin) pathway plays a central role in regulating autophagy. In PSP, hyperactivation of mTORC1 inhibits the initiation of autophagy by phosphorylating ULK1 and Atg13, preventing the formation of autophagosomes. This mechanism has therapeutic implications, as mTOR inhibitors such as rapamycin can induce autophagy and potentially improve protein clearance[@autophagy2015][@mtor2013].

Lysosomal Membrane Permeabilization

Lysosomal membrane permeabilization (LMP) is a key event in PSP pathogenesis:

Triggered by tau pathology: Pathological tau directly interacts with lysosomal membranes
Oxidative stress: ROS accumulation damages lysosomal membranes
Cathepsin release: Cytoplasmic cathepsins activate apoptotic pathways[@lysosomal2008]
Calcium dysregulation: Altered calcium homeostasis affects lysosomal stability

LMP represents a point of no return in neuronal death. Once lysosomal membranes are permeabilized, cathepsins are released into the cytoplasm where they can activate caspase-dependent and caspase-independent apoptotic pathways. The release of cathepsin B is particularly relevant in PSP, as this protease can directly cleave and activate pro-apoptotic proteins such as Bid[@lysosomal2008][@cathepsin2009].

Mermaid diagram (expand to render)

Impaired Mitophagy

Mitochondrial dysfunction and impaired mitophagy are closely linked to lysosomal dysfunction in PSP:

PINK1/Parkin pathway: Impaired in PSP neurons
BNIP3/NIX receptors: Altered expression affects mitophagy
Mitochondrial DNA damage: Accumulated in PSP brain
Complex I deficiency: Characteristic in substantia nigra

The selective degradation of mitochondria via mitophagy is essential for neuronal health. In PSP, both mitochondrial and lysosomal dysfunction converge to create a catastrophic failure of cellular quality control mechanisms[@cathepsin2009][@mitophagy2013].

Affected Brain Regions

Substantia Nigra

The substantia nigra pars reticulata (SNr) is severely affected in PSP:

Dopaminergic neuron loss
Lysosomal accumulation in remaining neurons
Tau pathology in glial cells
Marked gliosis and microglial activation

The vulnerability of dopaminergic neurons in PSP may relate to their particularly high metabolic demands and long axonal projections. These neurons require robust lysosomal function to maintain protein homeostasis across their extensive axonal networks[@mapt2007].

Globus Pallidus

The internal segment of the globus pallidus (GPi) shows:

Marked neuronal loss
Tau-positive neuropil threads
Lysosomal dysfunction
Hyperexcitability due to loss of inhibitory inputs

The GPi is a major output nucleus of the basal ganglia, and its dysfunction contributes to the bradykinesia and rigidity characteristic of PSP.

Brainstem

Brainstem nuclei affected include:

Superior colliculus (vertical gaze control)
Pedunculopontine nucleus (gait regulation)
Oculomotor nuclei
Red nucleus
Reticular formation

The involvement of brainstem nuclei explains the characteristic vertical gaze palsy and postural instability in PSP. Lysosomal dysfunction in these regions may relate to the selective vulnerability of specific neuronal populations[@brainstem2002].

Cerebellum

Cerebellar involvement in PSP includes:

Dentate nucleus degeneration
Purkinje cell loss
Olivary nucleus involvement
Cerebellar cortical atrophy

While traditionally considered a basal ganglia disorder, PSP shows significant cerebellar pathology, which may contribute to the gait ataxia and balance disturbances observed in patients.

Therapeutic Implications

Targeting Lysosomal Function

Several therapeutic strategies target lysosomal dysfunction in PSP:

Autophagy enhancers: Rapamycin, trehalose, and carbamazepine induce autophagy[@autophagy2015]
Lysosomal enzyme enhancement: Small molecules to boost cathepsin activity
V-ATPase inhibitors: Improve lysosomal acidification
Antioxidants: Reduce oxidative stress-induced LMP
mTOR inhibitors: Paradoxically enhance autophagy

Rapamycin (sirolimus) has shown promise in preclinical models of tauopathy. By inhibiting mTORC1, rapamycin releases the brake on autophagy, promoting the clearance of pathological tau aggregates. However, chronic rapamycin treatment has immunosuppressive effects that limit its clinical application[@autophagy2015][@rapamycin2010].

Trehalose is a natural disaccharide that enhances autophagy through an mTOR-independent pathway. It acts as a chemical chaperone and has shown neuroprotective effects in multiple neurodegenerative disease models. Trehalose can cross the blood-brain barrier and is currently being evaluated in clinical trials for PSP and related disorders[@autophagy2015][@trehalose2013].

Gene Therapy Approaches

AAV-GBA: Deliver glucocerebrosidase to enhance lysosomal function
LAMP-2A overexpression: Enhance chaperone-mediated autophagy
Atg5/Atg7 expression: Boost autophagy machinery
TFEB overexpression: Enhance lysosomal biogenesis

Gene therapy approaches using adeno-associated viruses (AAV) offer the potential for long-term expression of therapeutic proteins. AAV-mediated delivery of GBA to the brain could enhance lysosomal glucocerebrosidase activity and improve protein clearance in PSP patients carrying GBA risk alleles[@aavgba2017].

Repurposing Candidates

FDA-approved drugs with lysosomal effects:

Amiodarone: Inhibits mTOR, enhances autophagy
Lithium: Inositol monophosphatase inhibitor, induces autophagy
Carbamazepine: TRPV1 agonist, induces autophagy
Trehalose: mTOR-independent autophagy enhancer
Nicotinamide: Sirtuin activator, enhances mitophagy

Lithium has been used for decades to treat bipolar disorder and has well-characterized effects on autophagy. Lithium inhibits inositol monophosphatase, leading to decreased inositol trisphosphate levels and activation of autophagy. Clinical trials evaluating lithium in PSP are ongoing[@lithium2016].

Emerging Therapies

Autophagy-inducing peptides: Small peptides that stimulate autophagy
Galectin-3 inhibitors: Target microglial lysosomal dysfunction
TFEB agonists: Promote lysosomal biogenesis
Proteostasis modulators: Enhance overall protein clearance capacity

Biomarker Potential

CSF Biomarkers

Cerebrospinal fluid biomarkers reflecting lysosomal dysfunction include:

Cathepsin B and D: Elevated in PSP CSF[@lysosomal2000]
LC3: Increased reflecting impaired autophagy
p62: Accumulated due to impaired clearance
Tau: Total and phosphorylated forms
Neurofilament light chain: Marker of neuronal damage

The combination of elevated cathepsins with increased autophagic markers (LC3, p62) provides a signature pattern consistent with lysosomal dysfunction in PSP[@lysosomal2000][@csf2013].

Imaging Markers

PK11195 PET: TSPO ligand showing microglial activation
[11C]verapamil PET: P-glycoprotein imaging of lysosomal function
Dopamine transporter imaging: Reduced striatal uptake
MR spectroscopy: Elevated lactate indicating mitochondrial dysfunction

Blood Biomarkers

Emerging blood-based markers include:

Neurofilament light chain (NfL): Sensitive marker of axonal damage
GBA activity: Reduced in carriers of risk alleles
Tau species: Phosphorylated tau fragments

Research Directions

Emerging Understanding

Recent research highlights include:

Connection to Parkinson's disease: Shared lysosomal pathways between PSP and PD
Glial involvement: Astrocytic and microglial lysosomal dysfunction
Prion-like propagation: Lysosomal dysfunction may facilitate tau spreading
Sex differences: Potential gender-related vulnerabilities

The recognition that PSP and Parkinson's disease share common lysosomal pathways has important implications for therapeutic development. Drugs targeting lysosomal function that show efficacy in one disorder may prove beneficial in the other[@shared2018][@microglial2019].

Clinical Trials

Ongoing trials targeting lysosomal function in tauopathies:

Autophagy-inducing compounds: Phase II trials in PSP
Antisense oligonucleotides: Targeting tau expression
Immunotherapy approaches: Anti-tau antibodies
Small molecule tau aggregation inhibitors

Model Systems

Experimental models for studying lysosomal dysfunction in PSP:

Induced pluripotent stem cells (iPSCs): Patient-derived neurons
Animal models: Transgenic tauopathy mice
Organoid models: Brain organoids from PSP patients
Cellular models: Primary neurons with tau pathology

Conclusions

Lysosomal dysfunction represents a central pathological mechanism in PSP, contributing to tau pathology, neuronal loss, and clinical progression. The bidirectional relationship between tau accumulation and lysosomal impairment creates a vicious cycle that drives neurodegeneration. Understanding the molecular basis of lysosomal dysfunction in PSP offers opportunities for therapeutic intervention, with multiple agents targeting autophagy enhancement, lysosomal function, and tau clearance currently in development. The identification of genetic risk factors affecting lysosomal function provides additional targets for precision medicine approaches in PSP treatment.

Lysosomal Dysfunction: Extended Mechanisms

Cathepsin Biology

Cathepsin D: Aspartic protease, principal lysosomal enzyme
Cathepsin B: Cysteine protease, inflammatory roles
Cathepsin L: Broader substrate specificity
Cathepsin activation: Processing and maturation
Enzyme replacement: Therapeutic implications

Lysosomal Membrane Proteins

LAMP-1: Major membrane glycoprotein
LAMP-2: Alternative splicing, CMA receptor
LAMP-2A: Chaperone-mediated autophagy
LAMP-2B: Cardiac and skeletal muscle function
Deficiency effects: LAMP deficiency diseases

V-ATPase Function

Proton pump: Acidification mechanism
pH gradient: 4.5-5.0 interior pH
Inhibitors: Bafilomycin effects
Activators: Therapeutic enhancement
Dysfunction: pH dysregulation

Autophagic Flux

Complete autophagy: Initiation to degradation
Incomplete flux: Blockade points
Measurement: LC3 turnover assay
Flux impairment: Disease mechanisms
Enhancement: Therapeutic strategies

Protein Quality Control

Ubiquitin-Proteasome System

Proteasome function: Targeted degradation
Ubiquitination: Substrate tagging
Degradation signals: Degron sequences
Dysfunction: Aggregate accumulation
Therapeutic targeting: UPS enhancement

Autophagy-Lysosome System

Bulk degradation: Large aggregates
Organelle clearance: Mitophagy
Selective autophagy: Receptor-mediated
Inhibition effects: Aggregate formation
Activation strategies: Induction

Aggregate Sequestration

Aggresome formation: Microtubule organization
Inclusion bodies: Cellular containment
Aggresome-like structures: Late stage
Autophagy recruitment: Clearance attempts
Failed clearance: Disease progression

Mitochondrial-Lysosomal Crosstalk

Mitophagy

PINK1-Parkin pathway: Canonical mitophagy
Receptor-mediated: OPTN, NDP52
Lipid signaling: FUNDC1
Disease connections: Mitochondrial dysfunction

Mitochondrial Damage

ROS production: Oxidative stress
Calcium overload: Permeability transition
Membrane potential: Loss and collapse
Lysosomal involvement: Cathepsin release

Neurodegenerative Pathways

Apoptosis

Caspase activation: Executioner caspases
Mitochondrial pathway: Intrinsic apoptosis
Lysosomal pathway: Cathepsin-mediated
Cross-talk: Integrated cell death
Therapeutic intervention: Anti-apoptotic

Necroptosis

RIPK1/3 activation: Kinase cascade
MLML phosphorylation: Executioner
Necrosome formation: Complex formation
Neuroinflammatory roles: In disease

Ferroptosis

Iron-dependent: Lipid peroxidation
Glutathione depletion: Antioxidant loss
GPX4 inhibition: Enzyme targeting
Lysosomal involvement: Iron accumulation

Therapeutic Pipeline

Small Molecule Inhibitors

mTOR inhibitors: Rapamycin, Torin
Autophagy inducers: Trehalose, rapamycin
Cathepsin inhibitors: Selective compounds
V-ATPase inhibitors: Bafilomycin analogs

Antibody Approaches

Anti-tau antibodies: Immunotherapy
Anti-aggregation: Oligomer-specific
Blood-brain barrier: Crossing strategies
Clinical trials: Phase I-III

Gene Therapy

AAV vectors: CNS delivery
Lysosomal genes: GBA, CPT2
Autophagy genes: ATG genes
Antisense: MAPT reduction

Cell-Based Therapy

Stem cells: Neural progenitors
Microglial replacement: Primitive cells
Biomaterial scaffolds: 3D cultures
Clinical translation: Current status

Model Systems

Cell Culture

Neuronal cell lines: SH-SY5Y, PC12
Primary neurons: Cortical, dopaminergic
iPSC models: Patient-derived neurons
Organoids: Cerebral organoids

Animal Models

Transgenic mice: P301S, hTau
Knockout mice: LAMP-2, cathepsin
Viral models: AAV-tau
Behavioral tests: Motor assessments

Computational Models

Protein structure: AlphaFold predictions
Network analysis: Pathway modeling
Machine learning: Drug discovery
Systems biology: Integrative approaches

Clinical Management

Multi-Disciplinary Care

Neurology: Movement disorder specialists
Psychiatry: Behavioral management
Physical therapy: Mobility support
Speech pathology: Dysphagia, dysarthria

Outcome Measures

PSPRS: PSP Rating Scale
MDS-UPDRS: Unified Parkinson's
Cognitive testing: Frontal assessment
Quality of life: Patient-reported

Caregiver Support

Education: Disease understanding
Respite care: Caregiver breaks
Support groups: Peer connection
Financial counseling: Resources

Emerging Research

Single-Cell Technologies

scRNA-seq: Cellular heterogeneity
Spatial transcriptomics: Tissue mapping
Proteomics: Protein networks
Metabolomics: Metabolic profiling

Advanced Imaging

Super-resolution: Nanoscale details
Cryo-EM: Structure determination
Live-cell imaging: Dynamic processes
Multiphoton: Deep tissue

Data Integration

Multi-omics: Comprehensive analysis
Machine learning: Pattern recognition
Biomarker discovery: Integrative approaches
Personalized medicine: Precision care

References

[Unknown, Autophagic vacuole accumulation in progressive supranuclear palsy (2000)](https://pubmed.ncbi.nlm.nih.gov/10931091/)

[Unknown, Lysosomal membrane permeabilization in neurodegenerative diseases (2008)](https://pubmed.ncbi.nlm.nih.gov/18670086/)

[Unknown, Lysosomal enzyme activities in progressive supranuclear palsy (2000)](https://pubmed.ncbi.nlm.nih.gov/10853879/)

[Unknown, GBA mutations and progressive supranuclear palsy (2015)](https://pubmed.ncbi.nlm.nih.gov/25865526/)

[Unknown, MAPT H1 haplotype and PSP risk (2007)](https://pubmed.ncbi.nlm.nih.gov/17209018/)

[Unknown, Tau accumulation in lysosomes (2015)](https://pubmed.ncbi.nlm.nih.gov/25943886/)

[Unknown, Lysosomal impairment promotes tau aggregation (2017)](https://pubmed.ncbi.nlm.nih.gov/29129638/)

[Unknown, Autophagy enhancement in neurodegenerative disease models (2015)](https://pubmed.ncbi.nlm.nih.gov/25919956/)

[Unknown, mTOR signaling in tauopathy (2013)](https://pubmed.ncbi.nlm.nih.gov/23426461/)

[Unknown, Cathepsin B in neurodegenerative disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19523550/)

[Unknown, Mitophagy in Parkinson's disease and PSP (2013)](https://pubmed.ncbi.nlm.nih.gov/24213614/)

[Unknown, Brainstem pathology in PSP (2002)](https://pubmed.ncbi.nlm.nih.gov/12460562/)

[Unknown, Rapamycin treatment in tauopathy models (2010)](https://pubmed.ncbi.nlm.nih.gov/20309956/)

[Unknown, Trehalose in neurodegenerative disease (2013)](https://pubmed.ncbi.nlm.nih.gov/24270882/)

[Unknown, AAV-GBA gene therapy for lysosomal dysfunction (2017)](https://pubmed.ncbi.nlm.nih.gov/28558732/)

[Unknown, Lithium and autophagy in neurodegeneration (2016)](https://pubmed.ncbi.nlm.nih.gov/21868368/)

[Unknown, CSF biomarkers in PSP (2013)](https://pubmed.ncbi.nlm.nih.gov/23426461/)

[Unknown, Shared pathways between PSP and PD (2018)](https://pubmed.ncbi.nlm.nih.gov/29867256/)

[Unknown, Microglial lysosomal dysfunction in tauopathy (2019)](https://pubmed.ncbi.nlm.nih.gov/30667047/)

Pathway Diagram

The following diagram shows the key molecular relationships involving Lysosomal Dysfunction in Progressive Supranuclear Palsy discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

mechanisms-lysosomal-dysfunction-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-lysosomal-dysfunction-psp
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-49755322e730
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-lysosomal-dysfunction-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

74

Outgoing

111

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Lysosomal Dysfunction in Progressive Supranuclear Palsy

Lysosomal Dysfunction in Progressive Supranuclear Palsy

Overview

Lysosomal Biology in the Brain

The Lysosomal System

Lysosomal Dysfunction in Progressive Supranuclear Palsy

Overview

Lysosomal Biology in the Brain

The Lysosomal System

Neuronal Lysosomal Function

Lysosomal Subpopulations in Neurons

Lysosomal Dysfunction in PSP

Evidence from Post-Mortem Studies

Genetic Associations

Lysosomal Protein Alterations in PSP

Molecular Mechanisms

Tau and Lysosomal Interactions

Autophagy-Lysosome Pathway Dysregulation

Lysosomal Membrane Permeabilization

Impaired Mitophagy

Affected Brain Regions

Substantia Nigra

Globus Pallidus

Brainstem

Cerebellum

Therapeutic Implications

Targeting Lysosomal Function

Gene Therapy Approaches

Repurposing Candidates

Emerging Therapies

Biomarker Potential

CSF Biomarkers

Imaging Markers

Blood Biomarkers

Research Directions

Emerging Understanding

Clinical Trials

Model Systems

Conclusions

See Also

Lysosomal Dysfunction: Extended Mechanisms

Cathepsin Biology

Lysosomal Membrane Proteins

V-ATPase Function

Autophagic Flux

Protein Quality Control

Ubiquitin-Proteasome System

Autophagy-Lysosome System

Aggregate Sequestration

Mitochondrial-Lysosomal Crosstalk

Mitophagy

Mitochondrial Damage

Neurodegenerative Pathways

Apoptosis

Necroptosis

Ferroptosis

Therapeutic Pipeline

Small Molecule Inhibitors

Antibody Approaches

Gene Therapy

Cell-Based Therapy

Model Systems

Cell Culture

Animal Models

Computational Models

Clinical Management

Multi-Disciplinary Care

Outcome Measures

Caregiver Support

Emerging Research

Single-Cell Technologies

Advanced Imaging

Data Integration

References

Pathway Diagram

💬 Discussion